On Chen, MD
Interventional Cardiology · Stony Brook, NYNPI 1750681912
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,710 of the $141,322 with a category attached, or 75.5%. 31 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 33.6% of the total. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $350.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$47K
- Amgen$45K
- Bayer$26K
- Penumbra, Inc.$9K
- Abiomed$3K
- Abbott$3K
- plus $8K from 25 others
Across 34 payments — averaging $14,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$179K
- Amgen$166K
- Boehringer Ingelheim International GmbH$86K
- Boehringer Ingelheim Pharma GmbH & Co.kg$65K
- Eli Lilly$168
What the payments were for
- Consulting fees$7,8436%
- Speaking & faculty fees$106,71076%
- Travel & lodging$9,8547%
- Food & beverage$16,89712%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 104 | $47,426 |
| Amgen | 64 | $45,200 |
| Bayer | 17 | $25,595 |
| Penumbra, Inc. | 24 | $8,864 |
| Abiomed | 34 | $3,182 |
| Abbott | 9 | $2,951 |
| Medtronic(2 entities) | 25 | $1,860 |
| Chiesi USA, Inc. | 8 | $1,145 |
| Novartis | 28 | $1,078 |
| Boston Scientific | 15 | $722 |
| Shockwave Medical, Inc | 14 | $664 |
| Philips North America LLC | 6 | $559 |
| Janssen Scientific Affairs, LLC | 5 | $420 |
| Regeneron | 4 | $227 |
| Boehringer Ingelheim | 6 | $215 |
| Regeneron Healthcare Solutions, Inc. | 5 | $195 |
| AstraZeneca | 3 | $147 |
| Merck | 8 | $139 |
| Heartflow, Inc. | 2 | $132 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Scpharmaceuticals Inc. | 5 | $123 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $118 |
| Cardiva Medical, Inc. | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $32 |
| Terumo Medical Corporation | 1 | $26 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Asahi Intecc USA, Inc. | 1 | $17 |
| Cardinal Health 200 LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$45,230
- Repatha$44,140
- Kerendia$25,516
- Indigo System$8,383
- DRAGONFLY OPSTAR$2,500
- Impella$2,142
- KENGREAL$1,000
- ONYX FRONTIER$955
- LEQVIO$516
- Resolute$487
- XARELTO$318
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$295
- (5091) Amb Mon & Diag Und$264
- AVVIGO Guidance System$198
- SYNERGY$150
- Turbo Elite$142
- OPTIS$138
- Mitra Clip system$125
- NEXLIZET$125
- NEXLETOL$125
How this compares
$141,322 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 54 | $66,955 |
| EntrestoSacubitril/Valsartan | 43 | $52,723 |
| Repatha SureclickEvolocumab | 35 | $35,815 |
| Repatha SyringeEvolocumab | 21 | $22,943 |
| EliquisApixaban | 23 | $22,383 |
| BrilintaTicagrelor | 18 | $18,494 |
| Ezetimibe | 133 | $4,121 |
| Metoprolol Succinate | 90 | $1,677 |
| Rosuvastatin Calcium | 86 | $1,512 |
| Valsartan | 18 | $1,236 |
| Atorvastatin Calcium | 102 | $1,012 |
| Carvedilol | 101 | $1,002 |
| Spironolactone | 68 | $726 |
| Nifedipine ErNifedipine | 23 | $715 |
| ClopidogrelClopidogrel Bisulfate | 64 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $215 | $66,95554 claims |
| NovartisEntresto | $1,078 | $52,72343 claims |
| AstraZenecaBrilinta | $147 | $18,49418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Stony Brook
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.